Published in Expert Opin Ther Pat on February 04, 2013
The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52
p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis (2013) 0.89
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget (2015) 0.85
Battle against cancer: an everlasting saga of p53. Int J Mol Sci (2014) 0.83
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One (2014) 0.80
Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals (Basel) (2016) 0.77
An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC Clin Pathol (2013) 0.76
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci (2016) 0.76
p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells. Mol Cell Biol (2015) 0.76
2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists. Bioorg Med Chem Lett (2015) 0.76
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors. ACS Med Chem Lett (2016) 0.75
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf(-/-) mouse model. Proc Natl Acad Sci U S A (2017) 0.75
Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells. Oncotarget (2015) 0.75
Lifeact: a versatile marker to visualize F-actin. Nat Methods (2008) 12.23
Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci (2006) 2.79
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle (2009) 2.11
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle (2008) 1.71
Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure (2013) 1.63
Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med (2012) 1.61
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle (2007) 1.55
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 1.52
Automated Greulich-Pyle bone age determination in children with chronic kidney disease. Pediatr Nephrol (2015) 1.39
Expansion of the genetic code enables design of a novel "gold" class of green fluorescent proteins. J Mol Biol (2003) 1.34
Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc (2011) 1.30
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl (2011) 1.30
Practical aspects of the 2D 15N-[1h]-NOE experiment. J Biomol NMR (2002) 1.29
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem (2008) 1.27
Protein folding and stability of human CDK inhibitor p19(INK4d). J Mol Biol (2002) 1.25
Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant (2011) 1.24
Protein solubility: sequence based prediction and experimental verification. Bioinformatics (2006) 1.23
Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle (2010) 1.17
Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. Structure (2002) 1.15
The crystal structure of the non-liganded 14-3-3sigma protein: insights into determinants of isoform specific ligand binding and dimerization. Cell Res (2005) 1.13
Exfoliative toxins of Staphylococcus aureus. Toxins (Basel) (2010) 1.12
Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J Biol Chem (2005) 1.12
Molecular structure of the rod domain of dictyostelium filamin. J Mol Biol (2004) 1.12
The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice. J Biol Chem (2001) 1.11
Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A (2006) 1.11
Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest (2003) 1.10
Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem (2007) 1.09
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med (2005) 1.09
c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem (2008) 1.09
A novel matrix metalloprotease-like enzyme (karilysin) of the periodontal pathogen Tannerella forsythia ATCC 43037. Biol Chem (2010) 1.08
Backbone dynamics of green fluorescent protein and the effect of histidine 148 substitution. Biochemistry (2003) 1.08
Role of the ubiquitin-like protein Hub1 in splice-site usage and alternative splicing. Nature (2011) 1.07
Characterization of 14-3-3sigma dimerization determinants: requirement of homodimerization for inhibition of cell proliferation. Cell Cycle (2006) 1.07
1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des (2010) 1.07
Shugoshin is a Mad1/Cdc20-like interactor of Mad2. EMBO J (2011) 1.06
Efficient multicomponent reaction synthesis of the schistosomiasis drug praziquantel. Chemistry (2010) 1.06
Efficient and diverse synthesis of indole derivatives. J Org Chem (2009) 1.04
Efficient assembly of iminodicarboxamides by a "truly" four-component reaction. Angew Chem Int Ed Engl (2012) 1.03
Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. J Comb Chem (2010) 1.03
Slow exchange in the chromophore of a green fluorescent protein variant. J Am Chem Soc (2002) 1.02
Staphylococcal proteases aid in evasion of the human complement system. J Innate Immun (2013) 1.02
Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem (2011) 1.01
Polycyclic indole alkaloid-type compounds by MCR. Chem Commun (Camb) (2009) 1.01
Staphylococcus aureus-derived staphopain B, a potent cysteine protease activator of plasma chemerin. J Immunol (2007) 1.01
Structures of actin-bound Wiskott-Aldrich syndrome protein homology 2 (WH2) domains of Spire and the implication for filament nucleation. Proc Natl Acad Sci U S A (2010) 1.00
DNA-binding properties of the recombinant high-mobility-group-like AT-hook-containing region from human BRG1 protein. Biol Chem (2006) 0.99
Structure of the N-terminal domain of the FOP (FGFR1OP) protein and implications for its dimerization and centrosomal localization. J Mol Biol (2006) 0.99
The Gewald multicomponent reaction. Mol Divers (2010) 0.97
Prokaryotic toxin-antitoxin systems--the role in bacterial physiology and application in molecular biology. Acta Biochim Pol (2011) 0.97
Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J (2006) 0.96
Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Am Chem Soc (2005) 0.96
Tritylamine as an ammonia surrogate in the Ugi tetrazole synthesis. Org Lett (2013) 0.96
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. Bioorg Med Chem Lett (2006) 0.95
Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit (2002) 0.95
Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure (2005) 0.95
Robust NMR screening for lead compounds using tryptophan-containing proteins. J Am Chem Soc (2009) 0.95
A novel medium for expression of proteins selectively labeled with 15N-amino acids in Spodoptera frugiperda (Sf9) insect cells. J Biomol NMR (2003) 0.95
Functional and structural characterization of Spl proteases from Staphylococcus aureus. J Mol Biol (2006) 0.95
MCR synthesis of praziquantel derivatives. Chem Biol Drug Des (2012) 0.94
An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem (2007) 0.94
Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol (2005) 0.94
Cyanoacetamide multicomponent reaction (I): Parallel synthesis of cyanoacetamides. J Comb Chem (2009) 0.93
Adenoviral gene delivery to primary human cutaneous cells and burn wounds. Mol Med (2007) 0.93
Efficient C2 functionalisation of 2H-2-imidazolines. Org Biomol Chem (2007) 0.93
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Mol Cancer Ther (2007) 0.92
Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage. Biol Chem (2009) 0.92
Microbial degradation of microcystins. Chem Res Toxicol (2013) 0.92
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl (2014) 0.91
Ablation of cyclase-associated protein 2 (CAP2) leads to cardiomyopathy. Cell Mol Life Sci (2012) 0.91
Polycyclic compounds by Ugi-Pictet-Spengler sequence. J Org Chem (2010) 0.90
Efficient synthesis of arrays of amino acid derived Ugi products with subsequent amidation. J Comb Chem (2009) 0.90
The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem J (2008) 0.90
Structure of the N-terminal domain of the adenylyl cyclase-associated protein (CAP) from Dictyostelium discoideum. Structure (2003) 0.89
Design of a versatile multicomponent reaction leading to 2-amino-5-ketoaryl pyrroles. Chem Biol Drug Des (2010) 0.89
The three-dimensional structures of tick carboxypeptidase inhibitor in complex with A/B carboxypeptidases reveal a novel double-headed binding mode. J Mol Biol (2005) 0.88
Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. ACS Chem Biol (2014) 0.87
Cyanoacetamide MCR (III): three-component Gewald reactions revisited. J Comb Chem (2010) 0.87
On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS One (2012) 0.87
Desosamine in multicomponent reactions. Bioorg Med Chem Lett (2006) 0.87